去势抵抗性前列腺癌-话题@MedSci

#去势抵抗性前列腺癌#

112篇内容 | 2967人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1342130, encodeId=f66e134213075, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=N Engl J Med：奥拉帕尼治疗转移去势抵抗性前列腺癌研究 , objectType=article, longId=193420, objectId=c65519342036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65519342036, replyNumber=0, likeNumber=70, createdTime=2020-05-04, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65519342036, moduleTitle=N Engl J Med：奥拉帕尼治疗转移去势抵抗性前列腺癌研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65519342036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342129, encodeId=a4a013421290d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功, objectType=article, longId=193178, objectId=3bf01931e84c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bf01931e84c, replyNumber=0, likeNumber=78, createdTime=2020-05-01, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bf01931e84c, moduleTitle=AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bf01931e84c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342128, encodeId=4a70134212838, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, objectType=article, longId=192958, objectId=e2db19295879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2db19295879, replyNumber=0, likeNumber=62, createdTime=2020-04-27, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2db19295879, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2db19295879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342127, encodeId=57cf134212eef, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定, objectType=article, longId=192821, objectId=a90819282151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90819282151, replyNumber=0, likeNumber=68, createdTime=2020-04-24, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90819282151, moduleTitle=J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90819282151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342126, encodeId=5e8f134212603, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=BMC Cancer：去势抵抗性前列腺癌和骨转移的无症状患者使用镭223的效果, objectType=article, longId=192818, objectId=363519281838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=363519281838, replyNumber=0, likeNumber=83, createdTime=2020-04-24, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=363519281838, moduleTitle=BMC Cancer：去势抵抗性前列腺癌和骨转移的无症状患者使用镭223的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=363519281838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342125, encodeId=352d134212523, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Int J Clin Oncol：有症状去势抵抗性前列腺癌和骨转移患者的Radium-223二期研究的三年随访结果, objectType=article, longId=192817, objectId=f8e919281ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e919281ed8, replyNumber=0, likeNumber=50, createdTime=2020-04-24, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e919281ed8, moduleTitle=Int J Clin Oncol：有症状去势抵抗性前列腺癌和骨转移患者的Radium-223二期研究的三年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e919281ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342124, encodeId=3cd51342124bd, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, objectType=article, longId=190970, objectId=6cd81909e0c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd81909e0c0, replyNumber=0, likeNumber=77, createdTime=2020-03-29, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd81909e0c0, moduleTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd81909e0c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342123, encodeId=a98813421238d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer P D：去势抵抗性前列腺癌中阿比特龙和恩杂鲁胺的序贯治疗分析, objectType=article, longId=190743, objectId=50dd190e4383, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50dd190e4383, replyNumber=0, likeNumber=80, createdTime=2020-03-26, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50dd190e4383, moduleTitle=Prostate Cancer P D：去势抵抗性前列腺癌中阿比特龙和恩杂鲁胺的序贯治疗分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50dd190e4383)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342122, encodeId=dfad134212261, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Sci Rep：二线激素疗法治疗去势抵抗性前列腺癌的真实世界数据研究 , objectType=article, longId=190739, objectId=7456190e39e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7456190e39e6, replyNumber=0, likeNumber=77, createdTime=2020-03-26, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7456190e39e6, moduleTitle=Sci Rep：二线激素疗法治疗去势抵抗性前列腺癌的真实世界数据研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7456190e39e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342121, encodeId=684b13421212a, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究 , objectType=article, longId=190258, objectId=2c14190258a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c14190258a9, replyNumber=0, likeNumber=120, createdTime=2020-03-20, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c14190258a9, moduleTitle=J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c14190258a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342120, encodeId=9d8c13421207c, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估, objectType=article, longId=189491, objectId=50d918949101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50d918949101, replyNumber=0, likeNumber=51, createdTime=2020-03-08, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50d918949101, moduleTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50d918949101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342119, encodeId=4eb3134211974, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Cancer Immunol Immunother：混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究, objectType=article, longId=188409, objectId=717318840990, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=717318840990, replyNumber=0, likeNumber=107, createdTime=2020-02-21, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=717318840990, moduleTitle=Cancer Immunol Immunother：混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=717318840990)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342118, encodeId=787f1342118ae, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Sci Rep：循环miR-141和miR-375与转移去势抵抗性前列腺癌的治疗结果相关, objectType=article, longId=186706, objectId=885e186e0633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=885e186e0633, replyNumber=0, likeNumber=70, createdTime=2020-01-25, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=885e186e0633, moduleTitle=Sci Rep：循环miR-141和miR-375与转移去势抵抗性前列腺癌的治疗结果相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=885e186e0633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342117, encodeId=4109134211edb, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：DNA修复基因变异转移去势抵抗性前列腺癌患者中奥拉帕尼治疗研究, objectType=article, longId=186334, objectId=0b0c18633459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b0c18633459, replyNumber=0, likeNumber=68, createdTime=2020-01-17, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b0c18633459, moduleTitle=Lancet Oncol：DNA修复基因变异转移去势抵抗性前列腺癌患者中奥拉帕尼治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b0c18633459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342116, encodeId=2440134211673, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=JAMA Oncol：恩杂鲁胺治疗去势抵抗性前列腺癌男性中新的未确认骨病变与治疗结果相关性研究, objectType=article, longId=186005, objectId=3dc11860054c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc11860054c, replyNumber=0, likeNumber=0, createdTime=2020-01-11, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc11860054c, moduleTitle=JAMA Oncol：恩杂鲁胺治疗去势抵抗性前列腺癌男性中新的未确认骨病变与治疗结果相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc11860054c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342115, encodeId=3fc2134211599, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=JAMA Oncol：骨靶向放射性同位素治疗去势抵抗性前列腺癌骨转移男性的总生存研究, objectType=article, longId=185926, objectId=9c3d18592664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3d18592664, replyNumber=0, likeNumber=83, createdTime=2020-01-10, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3d18592664, moduleTitle=JAMA Oncol：骨靶向放射性同位素治疗去势抵抗性前列腺癌骨转移男性的总生存研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3d18592664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342114, encodeId=ef3113421140c, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测, objectType=article, longId=184869, objectId=7cbd18486903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cbd18486903, replyNumber=0, likeNumber=43, createdTime=2019-12-18, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cbd18486903, moduleTitle=2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cbd18486903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342113, encodeId=5b151342113b9, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=J Clin Oncol：派姆单抗治疗难治性转移去势抵抗性前列腺癌研究, objectType=article, longId=184303, objectId=d805184303b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d805184303b6, replyNumber=0, likeNumber=62, createdTime=2019-12-07, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d805184303b6, moduleTitle=J Clin Oncol：派姆单抗治疗难治性转移去势抵抗性前列腺癌研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d805184303b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342112, encodeId=c963134211263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Brit J Cancer：转移去势抵抗性前列腺癌中卡巴他赛治疗的总生存和无进展生存研究, objectType=article, longId=183826, objectId=dd531838266c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd531838266c, replyNumber=0, likeNumber=66, createdTime=2019-12-01, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd531838266c, moduleTitle=Brit J Cancer：转移去势抵抗性前列腺癌中卡巴他赛治疗的总生存和无进展生存研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd531838266c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342111, encodeId=fe411342111a9, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, objectType=article, longId=183078, objectId=978d1830e88d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978d1830e88d, replyNumber=0, likeNumber=65, createdTime=2019-11-17, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978d1830e88d, moduleTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978d1830e88d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

去势抵抗性前列腺癌

2020-05-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

N Engl J Med：奥拉帕尼治疗转移去势抵抗性前列腺癌研究

2020-05-04

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功

2020-05-01

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期

2020-04-27

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

J Nucl Med：177 Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量测定

2020-04-24

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

BMC Cancer：去势抵抗性前列腺癌和骨转移的无症状患者使用镭223的效果

2020-04-24

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Int J Clin Oncol：有症状去势抵抗性前列腺癌和骨转移患者的Radium-223二期研究的三年随访结果

2020-04-24

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！

2020-03-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer P D：去势抵抗性前列腺癌中阿比特龙和恩杂鲁胺的序贯治疗分析

2020-03-26

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Sci Rep：二线激素疗法治疗去势抵抗性前列腺癌的真实世界数据研究

2020-03-26

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究

2020-03-20

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估

2020-03-08

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Cancer Immunol Immunother：混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究

2020-02-21

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Sci Rep：循环miR-141和miR-375与转移去势抵抗性前列腺癌的治疗结果相关

2020-01-25

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：DNA修复基因变异转移去势抵抗性前列腺癌患者中奥拉帕尼治疗研究

2020-01-17

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

JAMA Oncol：恩杂鲁胺治疗去势抵抗性前列腺癌男性中新的未确认骨病变与治疗结果相关性研究

2020-01-11

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

JAMA Oncol：骨靶向放射性同位素治疗去势抵抗性前列腺癌骨转移男性的总生存研究

2020-01-10

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

2019 多学科共识文件：转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测

2019-12-18

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

J Clin Oncol：派姆单抗治疗难治性转移去势抵抗性前列腺癌研究

2019-12-07

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Brit J Cancer：转移去势抵抗性前列腺癌中卡巴他赛治疗的总生存和无进展生存研究

2019-12-01

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序

2019-11-17

科室
- - 订阅+
  - 更多科室
工具
服务